Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Travere Therapeutics Inc(TVTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TVTX
10/19/2026: TVTX (3-star) is currently NOT-A-BUY. Pass it for now.
Travere Therapeutics is a commercial-stage biotechnology company primarily focused on developing therapies for rare kidney and metabolic diseases. Its business strengths center on the commercial launch and regulatory success of its lead therapy, FILSPARI. The company's primary growth opportunity lies in expanding the use of its products to broader patient populations. However, investors must weigh these prospects against risks, including heavy product concentration, potential competition from larger pharmaceutical firms, and the ongoing need for capital as the company works toward sustained profitability. Travere is best suited for growth-oriented investors interested in rare disease therapeutics who are comfortable with the volatility inherent in biotechnology development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an active growth phase following the commercial launch of a lead product with potential for label expansion. |
| Momentum investor | Mixed fit | Momentum can be volatile and is highly dependent on clinical catalysts and market reception of sales data. |
| Value investor | Weak fit | As a loss-making biotech firm, standard value metrics like P/E are not currently applicable. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on growth and operations. |
| Low-risk investor | Weak fit | Biotech stocks face high clinical and regulatory risks that are generally unsuitable for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech valuations are highly sensitive to clinical news and regulatory events. |
| Valuation risk | Medium / high | The stock price relies on future expectations of success that may not materialize. |
| Competition risk | High | Large pharmaceutical entrants in nephrology could erode market share. |
| Business quality | Medium | The transition to a sustainable, profitable commercial entity is still in progress. |
| Dividend income | Low / none | No income generation is provided to shareholders. |
| Execution risk | High | Successful commercialization and trial outcomes are required to maintain long-term viability. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 315.26% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/19/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.61B USD | Price to earnings Ratio - | 1Y Target Price 75.21 |
Price to earnings Ratio - | 1Y Target Price 75.21 | ||
Volume (30-day avg) 1.8M shares | Beta 1.14 | 52 Weeks Range 22.59 - 68.73 | Updated Date 10/18/2026 |
52 Weeks Range 22.59 - 68.73 | Updated Date 10/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.74 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Rare Disease Pharmaceuticals | Revenue primarily from FILSPARI and legacy assets like THIOLA. | Revenue comes from selling high-cost, specialized drugs to treat chronic, rare medical conditions. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 39.84 | Enterprise Value 5.77B | Price to Sales(TTM) 7.91 |
Enterprise Value 5.77B | Price to Sales(TTM) 7.91 | ||
Enterprise Value to Revenue 9.75 | Enterprise Value to EBITDA 998.01 | Shares Outstanding 92.99M | Shares Floating 93.22M |
Shares Outstanding 92.99M | Shares Floating 93.22M | ||
Percent Insiders 0.69 | Percent Institutions 116.02 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.